Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

Kruis, W.; Frič, P.; Pokrotnieks, J.; Lukáš, M.; Fixa, B.; Kasščák, M.; Kamm, M. A.; Weismueller, J.; Beglinger, C.; Stolte, M.; Wolff, C.
November 2004
Gut;Nov2004, Vol. 53 Issue 11, p1617
Academic Journal
Background and aim: Evidence exists for the pathogenic role of the enteric flora in inflammatory bowel disease. Probiotics contain living microorganisms which exert health effects on the host. We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis. Patients and methods: In total, 327 patients were recruited and assigned to a double blind, double dummy trial to receive either the probiotic drug 200 mg once daily (n = 162) or mesalazine 500 mg three times daily (n = 165). The study lasted for 12 months and patients were assessed by clinical and endoscopic activity indices (Rachmilewitz) as well as by histology. The primary aim of the study was to confirm equivalent efficacy of the two drugs in the prevention of relapses. Results: The per protocol analysis revealed relapses in 40/110 (36.4%) patients in the E coli Nissle 1917 group and 38/112 (33.9%) in the mesalazine group (significant equivalence p = 0.003). Subgroup analyses showed no differences between the treatment groups in terms of duration and localisation of disease or pretrial treatment. Safety profile and tolerability were very good for both groups and were not different. Conclusions: The probiotic drug E coli Nissle 1917 shows efficacy and safety in maintaining remission equivalent to the gold standard mesalazine in patients with ulcerative colitis. The effectiveness of probiotic treatment further underlines the pathogenetic significance of the enteric flora.


Related Articles

  • Probiotic is useful for ulcerative colitis. Kruis, W.; Fric, P.; Pokrotnieks, J. // BMJ: British Medical Journal (International Edition);5/7/2005, Vol. 330 Issue 7499, Preceding p1035 

    Looks at the use of the probiotic Escherichia coli Nissle 1917 (EcN) in the treatment of ulcerative colitis. View that EcN is a Gram negative probiotic and may work by causing an immune response or preventing invasion of other bacteria; Review of study investigating the effect of EcN on...

  • A Population-based Ecologic Study of Inflammatory Bowel Disease: Searching for Etiologic Clues. Chris Green; Lawrence Elliott; Carole Beaudoin; Charles N. Bernstein // American Journal of Epidemiology;Oct2006, Vol. 164 Issue 7, p615 

    The authors' objective in this study was to determine geographic variations in the incidence of inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis, in the Canadian province of Manitoba and its association with the sociodemographic, geographic, and...

  • PHLEGMASIA CERULEA DOLENS AND ULCERATIVE COLITIS. Woolling, Kenneth R.; Lawrance, Kingsley; Rosenak, Bernard D. // Angiology;Sep1967, Vol. 18 Issue 9, p556 

    A case of chronic ulcerative colitis with phlegmasia cerulea dolens requiring almost total limb amputation is reported. The patient developed shock, massive gangrene of the left lower extremity and general sepsis, yet recovered and during the ensuing 2 years has acquired a prosthesis and...

  • CITATIONS AND CLINICIANS' NOTES: INFLAMMATORY BOWEL DISEASE.  // Current Medical Literature: Gastroenterology;2005, Vol. 24 Issue 2, p37 

    Comments on previously published studies on inflammatory bowel disease and related topics. Interventions for treating collagenous colitis; Inflammatory bowel disease in pediatric and adolescent patients; Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on...

  • Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations. Maul, Jochen; Zeitz, Martin // Langenbeck's Archives of Surgery;Jan2012, Vol. 397 Issue 1, p1 

    Background: Ulcerative colitis (UC) is a complex disease in which the interaction of genetic, environmental and microbial factors drives chronic intestinal inflammation that finally leads to extensive tissue fibrosis. Discussion: The present review discusses the current knowledge on genetic...

  • Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Higgins, P. D. R.; Schwartz, M.; Mapili, J.; Krokos, I.; Leung, J.; Zimmermann, E. M. // Gut;Jun2005, Vol. 54 Issue 6, p782 

    Background and aims: Ulcerative colitis disease activity indices offer good statistical power but small changes in these indices may not be clinically important. There are no validated definitions of remission or of significant improvement for these indices. The use of clinically important end...

  • Selected Individual Therapeutic Problems in Inflammatory Bowel Disease. Kirsner, Joseph B.; Deutsch, Stephen; Hanauer, Stephen B. // American Journal of Gastroenterology;May1984, Vol. 79 Issue 5, p368 

    Presents ten selected individual therapeutic problems in inflammatory bowel disease. Information on the successful therapy for ulcerative colitis; Problem on the case of 30-year old female audiologist with ulcerative colitis; Explanation on the initial difficulty in clinically differentiating...

  • Early surgical intervention in ulcerative colitis. Cima, R. R.; Pemberton, J. H. // Gut;Feb2004, Vol. 53 Issue 2, p306 

    This article focuses on the early surgical intervention in ulcerative colitis (UC), which is one of the major categories of inflammatory bowel disease and is characterised by chronic colonic mucosal inflammation of unknown aetiology. There are three major indications for surgical intervention in...

  • New Studies on the Role of Smoking in Inflammatory Bowel Disease: Are We Not Beating a Dead Horse? Picco, Michael F. // American Journal of Gastroenterology;Mar2007, Vol. 102 Issue 3, p598 

    The role of smoking in inflammatory bowel disease (IBD) has drawn more interest as our understanding of these diseases has moved beyond the simple designations of Crohn's disease (CD) and ulcerative colitis (UC). In this issue of the journal, Aldous et al. present two papers on the role of...


Read the Article


Sign out of this library

Other Topics